T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road
T-cells have a natural ability to fight cancer cells in the tumour microenvironment. Due to thymic selection and tissue-driven immunomodulation, these cancer-fighting T-cells are generally low in number and exhausted. One way to overcome these issues is to genetically alter T-cells to improve their...
Main Authors: | Michael D. Crowther, Inge Marie Svane, Özcan Met |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-06-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/7/1588 |
Similar Items
-
Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020)
by: Nikola A. Ivica, et al.
Published: (2021-08-01) -
CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
by: Delong Liu
Published: (2019-11-01) -
Bispecific Antibody Format and the Organization of Immunological Synapses in T Cell-Redirecting Strategies for Cancer Immunotherapy
by: Carlos Carrasco-Padilla, et al.
Published: (2022-12-01) -
Novel Immunotherapies for Osteosarcoma
by: Yubao Lu, et al.
Published: (2022-04-01) -
CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More
by: Xuejin Ou, et al.
Published: (2021-05-01)